Jan Schnalke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Schnalke has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Johanna Risse
Institute for Medical Humanities, Medizinische Fakultät, Universitätsklinikum Bonn Bonn Germany
2 shared publications - Thomas Heinemann
Institute for Medical Humanities, Medizinische Fakultät, Universitätsklinikum Bonn Bonn Germany
2 shared publications - Hans-Georg Dederer
Universität Passau
1 shared publication - Lothar Pietrek
Lehrstuhl für Staats- und Verwaltungsrecht, Völkerrecht, Europäisches und Internationales Wirtschaftsrecht, Universität Passau Passau Germany
1 shared publication Merlin Krzemien
Institute for Medical Humanities, University Hospital Bonn, Bonn, Germany
1 shared publication- Merlin Krzemien
Institute for Medical Humanities, Medical Faculty, University of Bonn, Venusberg-Campus 1, 53127, Bonn, Germany
1 shared publication
Latest Publications
- Open Access
- 11 August 2025
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 28 (3) , 425-445
“Snip, snip, cure”? Philosophical, legal and biomedical perspectives on novel somatic genomic therapies
The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.
- 11 August 2025
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 28 (3) , 425-445
Open Access“Snip, snip, cure”? Philosophical, legal and biomedical perspectives on novel somatic genomic therapies
The advent of innovative techniques, such as the CRISPR/Cas system, has opened up a new range of possibilities for modifying the genome, with the potential to address previously unmet therapeutic needs of patients with genetic diseases. These new possibilities have not only raised ethical concerns but also challenged existing classifications of genome modification techniques. While the legal status of some of these new therapies remains uncertain, there is an ongoing debate within philosophy of biology about the information-related metaphors adopted by scientists to describe and classify the genome and its therapeutic modification. Given the continuing advance of new genomic therapies, we show, employing an interdisciplinary approach, that a comprehensive framework for the classification of these technologies is needed to resolve legal and philosophical issues. The first section provides an analysis of the current state of novel genome-modifying techniques in medical genetics. In the second section, we assess the regulatory status of these techniques within the European regulatory framework for advanced therapy medicinal products (ATMPs). Drawing on these results, we argue in the third section from a philosophical perspective that metaphors, such as ‘editing’ the genome, which are based on a conception of the genome as linear information, cannot adequately capture the breadth of advanced genomic technologies. To accurately categorise these techniques in a manner that meets their diverse applications, we propose introducing the umbrella term ‘somatic genomic therapies’ (SGTs). Urging an integrative approach to defining and classifying new technologies in medical genetics, we advocate for the development of an integrative concept of SGTs.
- Open Access
- 24 April 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (7-8) , 353-357
Towards ethical drug pricing: the European Orphan Genomic Therapies Fund
An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.
- 24 April 2024
- Published by Springer Nature in Gene Therapy
- Vol. 31 (7-8) , 353-357
Open AccessTowards ethical drug pricing: the European Orphan Genomic Therapies Fund
An increasing number of novel genomic therapies are expected to become available for patients with rare or ultra-rare diseases. However, the primary obstacle to equal patient access to these orphan genomic therapies are currently very high prices charged by manufacturers in the context of limited healthcare budgets. Taking into account ethical pricing theories, the paper proposes the implementation of a pricing infrastructure covering all European member states, which has the potential to promote distributive justice while maintaining the attractiveness of genomic therapy development.